A randomized double-blind placebo-controlled parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer s Disease (AD)
Brief description of study
The purpose of this study is to learn more about how CNP520 affects the body and how to better diagnose, monitor, and treat Alzheimer's Disease. Differences in DNA among people may explain why different people have different responses to the same drug, different risks of developing certain diseases, different disease progression, etc. Genetic research looks at how DNA relates to these differences. Genetic material and information can also be obtained from other substances in your biological samples, such as RNA, which is important in making proteins. Samples and data will be used to study scientific questions related to CNP520, or the risk for developing the symptoms of Alzheimer's disease or related diseases, or the development of drugs to treat people who are at risk for developing the symptoms of Alzheimer's disease or related diseases. The results of this study may be combined with results of other studies for pooled analysis and interpretation.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
